Literature DB >> 17003492

Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation.

Tetsuro Murakami1, Erwan Paitel, Takeshi Kawarabayashi, Masaki Ikeda, M Azhar Chishti, Christopher Janus, Etsuro Matsubara, Atsushi Sasaki, Toshitaka Kawarai, Amie L Phinney, Yasuo Harigaya, Patrick Horne, Nobuaki Egashira, Kenichi Mishima, Amanda Hanna, Jing Yang, Katsunori Iwasaki, Mitsuo Takahashi, Michihiro Fujiwara, Koichi Ishiguro, Catherine Bergeron, George A Carlson, Koji Abe, David Westaway, Peter St George-Hyslop, Mikio Shoji.   

Abstract

Recapitulation of tau pathologies in an animal model has been a long-standing goal in neurodegenerative disease research. We generated transgenic (TgTauP301L) mice expressing a frontotemporal dementia with parkinsonism linked to chromosome 17 (FTPD-17) mutation within the longest form of tau (2N, 4R). TgTauP301L mice developed florid pathology including neuronal pretangles, numerous Gallyas-Braak-positive neurofibrillary tangles, and glial fibrillary tangles in the frontotemporal areas of the cerebrum, in the brainstem, and to a lesser extent in the spinal cord. These features were accompanied by gliosis, neuronal loss, and cerebral atrophy. Accumulated tau was hyperphosphorylated, conformationally changed, ubiquitinated, and sarkosyl-insoluble, with electron microscopy demonstrating wavy filaments. Aged TgTauP301L mice exhibited impairment in hippocampally dependent and independent behavioral paradigms, with impairments closely related to the presence of tau pathologies and levels of insoluble tau protein. We conclude that TgTauP301L mice recreate the substantial phenotypic variation and spectrum of pathologies seen in FTDP-17 patients. Identification of genetic and/or environmental factors modifying the tau phenotype in these mice may shed light on factors modulating human tauopathies. These transgenic mice may aid therapeutic development for FTDP-17 and other diseases featuring accumulations of four-repeat tau, such as Alzheimer's disease, corticobasal degeneration, and progressive supranuclear palsy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003492      PMCID: PMC1698843          DOI: 10.2353/ajpath.2006.051250

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

Review 1.  Neurodegenerative tauopathies.

Authors:  V M Lee; M Goedert; J Q Trojanowski
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

2.  Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau.

Authors:  Kentaro Tanemura; Miyuki Murayama; Takumi Akagi; Tsutomu Hashikawa; Takashi Tominaga; Michinori Ichikawa; Haruyasu Yamaguchi; Akihiko Takashima
Journal:  J Neurosci       Date:  2002-01-01       Impact factor: 6.167

3.  Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein.

Authors:  Bridget Allen; Esther Ingram; Masaki Takao; Michael J Smith; Ross Jakes; Kanwar Virdee; Hirotaka Yoshida; Max Holzer; Molly Craxton; Piers C Emson; Cristiana Atzori; Antonio Migheli; R Anthony Crowther; Bernardino Ghetti; Maria Grazia Spillantini; Michel Goedert
Journal:  J Neurosci       Date:  2002-11-01       Impact factor: 6.167

4.  Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene.

Authors:  S M Pickering-Brown; A M T Richardson; J S Snowden; A M McDonagh; A Burns; W Braude; M Baker; W-K Liu; S-H Yen; J Hardy; M Hutton; Y Davies; D Allsop; D Craufurd; D Neary; D M A Mann
Journal:  Brain       Date:  2002-04       Impact factor: 13.501

5.  Selective deposition of mutant tau in the FTDP-17 brain affected by the P301L mutation.

Authors:  T Miyasaka; M Morishima-Kawashima; R Ravid; W Kamphorst; K Nagashima; Y Ihara
Journal:  J Neuropathol Exp Neurol       Date:  2001-09       Impact factor: 3.685

6.  Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration.

Authors:  Makoto Higuchi; Takeshi Ishihara; Bin Zhang; Ming Hong; Athena Andreadis; John Trojanowski; Virginia M-Y Lee
Journal:  Neuron       Date:  2002-08-01       Impact factor: 17.173

7.  Tau exon 10 +16 mutation FTDP-17 presenting clinically as sporadic young onset PSP.

Authors:  H R Morris; Y Osaki; J Holton; A J Lees; N W Wood; T Revesz; N Quinn
Journal:  Neurology       Date:  2003-07-08       Impact factor: 9.910

8.  Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms.

Authors:  Cathy Andorfer; Yvonne Kress; Marisol Espinoza; Rohan de Silva; Kerry L Tucker; Yves-Alain Barde; Karen Duff; Peter Davies
Journal:  J Neurochem       Date:  2003-08       Impact factor: 5.372

9.  Stress-induced hyperphosphorylation of tau in the mouse brain.

Authors:  Yasuhiro Okawa; Koichi Ishiguro; Shinobu C Fujita
Journal:  FEBS Lett       Date:  2003-01-30       Impact factor: 4.124

10.  Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation.

Authors:  Wen-Lang Lin; Jada Lewis; Shu-Hui Yen; Michael Hutton; Dennis W Dickson
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

View more
  26 in total

1.  Focal expression of mutated tau in entorhinal cortex neurons of rats impairs spatial working memory.

Authors:  Julio J Ramirez; Winona E Poulton; Erik Knelson; Cole Barton; Michael A King; Ronald L Klein
Journal:  Behav Brain Res       Date:  2010-08-19       Impact factor: 3.332

Review 2.  Knock-out and transgenic mouse models of tauopathies.

Authors:  Franziska Denk; Richard Wade-Martins
Journal:  Neurobiol Aging       Date:  2007-06-22       Impact factor: 4.673

Review 3.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

4.  Frontotemporal lobar degeneration-related proteins induce only subtle memory-related deficits when bilaterally overexpressed in the dorsal hippocampus.

Authors:  Robert D Dayton; David B Wang; Cooper D Cain; Lisa M Schrott; Julio J Ramirez; Michael A King; Ronald L Klein
Journal:  Exp Neurol       Date:  2011-12-09       Impact factor: 5.330

Review 5.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

Review 6.  Improved behavioral response as a valid biomarker for drug screening program in transgenic rodent models of tauopathies.

Authors:  Miroslava Korenova; Zuzana Stozicka
Journal:  Cell Mol Neurobiol       Date:  2009-03-13       Impact factor: 5.046

7.  Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice.

Authors:  Dave Morgan; Sanjay Munireddy; Jennifer Alamed; Jason DeLeon; David M Diamond; Paula Bickford; Michael Hutton; Jada Lewis; Eileen McGowan; Marcia N Gordon
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

8.  Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild-type human tau.

Authors:  Tetsuya Kimura; Shunji Yamashita; Tetsuya Fukuda; Jun-Mi Park; Miyuki Murayama; Tatsuya Mizoroki; Yuji Yoshiike; Naruhiko Sahara; Akihiko Takashima
Journal:  EMBO J       Date:  2007-11-15       Impact factor: 11.598

9.  Adult-onset focal expression of mutated human tau in the hippocampus impairs spatial working memory of rats.

Authors:  Martina L Mustroph; Michael A King; Ronald L Klein; Julio J Ramirez
Journal:  Behav Brain Res       Date:  2012-04-25       Impact factor: 3.332

10.  Tau is not necessary for amyloid-β-induced synaptic and memory impairments.

Authors:  Daniela Puzzo; Elentina K Argyrousi; Agnieszka Staniszewski; Hong Zhang; Elisa Calcagno; Elisa Zuccarello; Erica Acquarone; Mauro Fa'; Domenica D Li Puma; Claudio Grassi; Luciano D'Adamio; Nicholas M Kanaan; Paul E Fraser; Ottavio Arancio
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.